Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | GNRHR | P30968 | 1/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4019355 | 0.86 | PTGDR2 (0.35) | PTGDR2KMT2ABRD4CYP2D6GNRHR | |
| SCHEMBL5129060 | 0.86 | DYRK1A (0.42) | CNR2DYRK1ATDP1MEN1KMT2A | |
| SCHEMBL5128333 | 0.85 | PTGDR2 (0.35) | PTGDR2KIF11KMT2ABRD4CYP2D6 | |
| SCHEMBL5128358 | 0.83 | CNR2 (0.36) | CNR2TDP1PTGDR2MEN1KMT2A | |
| SCHEMBL5128346 | 0.82 | CHEK1 (0.41) | TDP1PTGDR2MEN1KMT2A | |
| SCHEMBL4005010 | 0.76 | DYRK1A (0.46) | CNR2DYRK1ATDP1BRD4STING1 | |
| SCHEMBL5126809 | 0.74 | ATR (0.39) | CNR2DYRK1ATDP1MEN1KMT2A | |
| SCHEMBL14192082 | 0.74 | PDE4A (0.35) | PTGDR2MEN1KMT2A | |
| SCHEMBL14192079 | 0.71 | ATR (0.37) | CNR2DYRK1AMEN1KMT2ABRD4 | |
| SCHEMBL4017813 | 0.71 | CHEK1 (0.33) | DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080114016-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2008-05-15 | — | — | US | disclosed |
| US-20080114016-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2008-05-15 | — | — | US | disclosed |
| EP-1835918-A2 | INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006074281-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114016-A1 | Inhibitors of Checkpoint Kinases | CHEK1, CHEK2, BUB1B | CNR2 4397/4885DYRK1A 634/4885SIGMAR1 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.